Fig. 3: Maintenance of LGR5-expressing cells in liver tumor organoids and allograft tumors.
From: LGR5 marks targetable tumor-initiating cells in mouse liver cancer
a, b Representative pictures showing organoid lines that predominately express the hepatocyte marker HNF4ɑ (a) or the cholangiocyte marker CK19 (b) (upper panels: IF staining; lower panels: bright-field microscopic pictures, scale bar = 50 µm). c Representative pictures showing the presence of LGR5- expressing cells in organoids. LGR5-driven GFP: green. Scale bar = 50 µm. d An outline of the experimental strategy used to transplant tumor organoid lines into immunodeficient mice. e The percentages of LGR5-expressing cells in allograft tumors and the corresponding primary tumors (primary vs. allograft: 2.8 ± 0.8% vs. 6.8 ± 5.6%, n = 11, P = 0.3577). f, g Representative pictures of allograft tumors that mainly express either the hepatocyte marker HNF4ɑ (f) or the cholangiocyte marker CK19 (g). Scale bar = 50 µm. Mean ± SEM. Source data are provided as a Source Data file.
